

Maternal hyperoxygenation therapy to stimulate left heart growth.

Shiqun Chen*

Department of Cardiology, Fengxian Branch of Shanghai 6th People's Hospital, China

Introduction

Maternal hyperoxygenation therapy is a groundbreaking approach that holds the potential to revolutionize prenatal care and improve the outcomes for infants with congenital heart defects (CHD). This innovative treatment aims to stimulate left heart growth in utero, addressing a critical aspect of CHD management. In this article, we will explore the concept of maternal hyperoxygenation therapy, its underlying principles, its current status in medical research, and the hopes it brings for a brighter, healthier future for infants with CHD. Congenital heart defects refer to structural abnormalities in the heart that exist from birth. These defects can range from minor issues that don't require treatment to severe, life-threatening conditions. One of the most common types of CHD is hypoplastic left heart syndrome (HLHS), where the left side of the heart doesn't develop properly, leading to reduced blood flow to the body. CHD poses a significant health challenge, affecting approximately 1% of all live births. Babies born with severe CHD often require complex surgeries, interventions, and long-term medical care. Despite advances in medical science and surgical techniques, the prognosis for infants with severe CHD remains challenging, making innovative approaches like maternal hyperoxygenation therapy a beacon of hope [1,2].

To understand maternal hyperoxygenation therapy, it's essential to comprehend the role of oxygen in prenatal development. During pregnancy, the fetus relies on oxygenated blood from the mother through the placenta. The oxygen-rich blood travels through the fetal heart, supporting the growth and development of various organ systems, including the heart itself. For infants with HLHS and other left heart-related CHDs, there is often an insufficient supply of oxygenated blood to the left side of the heart, hindering its development. This deficiency can lead to underdeveloped left heart structures, making surgical repair more challenging and less successful. Maternal hyperoxygenation therapy seeks to overcome this challenge by increasing the oxygen supply to the fetal left heart during pregnancy. The premise is straightforward: if you can provide the fetus with more oxygen during prenatal development, you can potentially stimulate left heart growth and improve outcomes for babies born with CHD. This therapy involves having the expectant mother inhale higher concentrations of oxygen for a specified period each day, typically in the third trimester of pregnancy. The increased oxygen in the mother's bloodstream is then transported to the fetus, potentially promoting left heart

growth. Researchers believe that this additional oxygen can encourage the development of the left ventricle, a critical component of the heart that is often underdeveloped in CHD cases. [3,4].

The science supporting maternal hyperoxygenation therapy is still evolving, but early studies show promise. Researchers hypothesize that the increased oxygen levels in the mother's blood could lead to a cascade of events that stimulate left heart growth: Increased Oxygen Delivery Oxygen is essential for cell growth and function. By providing more oxygen to the fetus, cells in the left side of the heart may have the resources they need to grow and develop properly. [5,6].

In CHD, there is often increased pulmonary vasoconstriction, which can divert blood away from the left side of the heart. Higher oxygen levels may help relax these blood vessels, redirecting more oxygen-rich blood to the left heart. Improved Myocardial Function: Adequate oxygen levels can support the myocardium (heart muscle) in its development, potentially leading to stronger left ventricular contractions. Maternal hyperoxygenation therapy is still in the experimental stage, with ongoing research efforts aimed at validating its effectiveness and safety. Clinical trials are underway to determine the therapy's impact on left heart growth and its potential to improve outcomes for infants with CHD. [7,8].

The preliminary results are encouraging. Some studies suggest that maternal hyperoxygenation therapy may indeed lead to improved left heart growth and function in fetuses with CHD. However, it's essential to emphasize that further research is needed to establish its efficacy conclusively. [9,10].

Conclusion

Maternal hyper oxygenation therapy represents a promising avenue in the field of prenatal care and congenital heart defect management. By addressing the crucial issue of left heart underdevelopment in utero, this innovative therapy offers new hope for infants born with CHD. While research is ongoing, the potential benefits of improved left heart growth and better surgical outcomes make maternal hyper oxygenation therapy a beacon of hope for both expectant parents and medical professionals. As we continue to delve deeper into the science behind this therapy, we inch closer to a brighter and healthier future for infants with congenital heart defects, one where innovative approaches like maternal hyper oxygenation therapy can significantly improve the quality of life for these young patients.

*Correspondence to: Shiqun Chen, Department of Cardiology, Fengxian Branch of Shanghai 6th People's Hospital, China., E-mail: AlShammeri56@gmail.com

Received: 25-Dec-2023, Manuscript No. AACC-24-130259; Editor assigned: 28-Dec-2024, Pre QC No. AACC-24-130259(PQ); Reviewed: 11-Jan-2024, QC No. AACC-24-130259;

Revised: 16-Jan-2024, Manuscript No. AACC-24-130259(R), Published: 22-Jan-2024, DOI:10.35841/aacc-8.1.241

References

1. Materson BJ. Variability in response to antihypertensive drugs. *Am J Med.* 2007; 120 (4 Suppl 1):S10-20.
2. Khosla T, Lowe CR. Indices of obesity derived from body weight and height. *Br J Prev Soc Med.* 1967; 21(3): 122-28.
3. Nuttall FQ. Body Mass Index: Obesity, BMI, and Health: A Critical Review. *Nutr Today.* 2015;50(3):117-128.
4. Etehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. *Lancet.* 2016; 387(10022):957-67.
5. Robinson TN. Television viewing and childhood obesity. *Pediatr Clin North Am.* 2001;48:1017-25.
6. Richardson P., McKenna RW., Bristow M., et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. *Circulation.* 1996;93(5):841-42.
7. Klop B, Elte JWF, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. *Nutrients.* 2013;5(4):1218-40.
8. Breinholt JP, Moulik M., Dreyer WJ., et al. Viral epidemiologic shift in inflammatory heart disease: the increasing involvement of parvovirus B19 in the myocardium of pediatric cardiac transplant patients. *J Heart Lung Transplant.* 2010;29(7):739-46.
9. Caforio ALP., Pankuweit S., Arbustini E., et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. *Eur Heart J.* 2013;34(33):2636-648.
10. Lowe GD, Rumley A, Woodward M, et al. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. *Br J Haematol.* 1997;97(4):775-784.